Crucial role of estrogen for the mammalian female in regulating semen coagulation and liquefaction in vivo

Shuai Li, Marleny Garcia, Rachel L. Gewiss, Wipawee Winuthayanon*

School of Molecular Biosciences, College of Veterinary Medicine, Washington State University, Pullman, Washington, United States of America

* winuthayanonw@vetmed.wsu.edu

Abstract

Semen liquefaction changes semen from a gel-like to watery consistency and is required for sperm to gain mobility and swim to the fertilization site in the Fallopian tubes. Kallikrein-related peptidases 3 (KLK3) and other kallikrein-related peptidases from male prostate glands are responsible for semen liquefaction by cleaving gel-forming proteins (semenogelin and collagen). In a physiological context, the liquefaction process occurs within the female reproductive tract. How seminal proteins interact with the female reproductive environment is still largely unexplored. We previously reported that conditional genetic ablation of \( \text{Esr}1 \) (estrogen receptor \( \alpha \)) in the epithelial cells of the female reproductive tract (\( \text{Wnt}7\alpha \text{Cre}^+/\);\( \text{Esr}1^{f/f} \)) causes female infertility, partly due to a drastic reduction in the number of motile sperm entering the oviduct. In this study, we found that post-ejaculated semen from fertile wild-type males was solidified and the sperm were entrapped in \( \text{Wnt}7\alpha \text{Cre}^+/\);\( \text{Esr}1^{f/f} \) uteri, compared to the watery semen (liquefied) found in \( \text{Esr}1^{f/f} \) controls. In addition, semenogelin and collagen were not degraded in \( \text{Wnt}7\alpha \text{Cre}^+/\);\( \text{Esr}1^{f/f} \) uteri. Amongst multiple gene families aberrantly expressed in the absence of epithelial ESR1, we have identified that a lack of \( \text{Klks} \) in the uterus is a potential cause for the liquefaction defect. Pharmacological inhibition of KLKs in the uterus replicated the phenotype observed in \( \text{Wnt}7\alpha \text{Cre}^+/\);\( \text{Esr}1^{f/f} \) controls. In addition, semenogelin and collagen were not degraded in \( \text{Wnt}7\alpha \text{Cre}^+/\);\( \text{Esr}1^{f/f} \) uteri. Amongst multiple gene families aberrantly expressed in the absence of epithelial ESR1, we have identified that a lack of \( \text{Klks} \) in the uterus is a potential cause for the liquefaction defect. Pharmacological inhibition of KLKs in the uterus replicated the phenotype observed in \( \text{Wnt}7\alpha \text{Cre}^+/\);\( \text{Esr}1^{f/f} \) uteri, suggesting that loss of uterine and seminal KLK function causes this liquefaction defect. In human cervical cell culture, expression of several KLKs and their inhibitors (\( \text{SPINKs} \)) was regulated by estrogen in an ESR1-dependent manner. Our study demonstrates that estrogen/ESR1 signaling in the female reproductive tract plays an indispensable role in normal semen liquefaction, providing fundamental evidence that exposure of post-ejaculated semen to the suboptimal microenvironment in the female reproductive tract leads to faulty liquefaction and subsequently causes a fertility defect.

Author summary

Semen liquefaction has been considered to be solely modulated by prostate-derived kallikrein-related peptidases (KLKs), especially KLK3 (or prostate specific antigen). However, our research demonstrated that female mice lacking estrogen receptor alpha (ER\( \alpha \)) in the
uterine epithelial cells had a drastic decrease in \( Klk \) transcripts and semen from fertile males fails to liquefy within the uteri of these females. Therefore, our results provide a novel aspect that, due to an interplay between semen and female reproductive tract secretions, the physiology of semen liquefaction is more complicated than previously assumed. This information will advance research on semen liquefaction in the female reproductive tract, an area that has never been explored, and could lead to the development of diagnostic tools for unexplained infertility cases and non-invasive contraception technologies.

**Introduction**

In the United States, approximately 46% of women are unable to conceive within the first 12 months of trying to get pregnant [1]. Infertile couples may experience psychological distresses, including low self-esteem, isolation, and depression. Cumulatively, the infertile couples in the United States have spent more than ~$5 billion per year for diagnosis and treatment in fertility clinics [2]. These circumstances emphasize the need for a better understanding of the causes of infertility.

In humans, a semen coagulum is composed of the secretory products from male accessory organs, including the prostate glands, seminal vesicles, and coagulating glands. After ejaculation, both semen and sperm are deposited to the anterior wall of the vagina, adjacent to the ectocervical tissues. In order for the sperm to travel through the reproductive tract to fertilize the eggs in the oviduct (or Fallopian tube in humans) [3], the semen must undergo the process of liquefaction. Congenital absence, obstruction, or surgical removal of the seminal vesicles causes sterility in men and rodents [4, 5], indicating that not only are the secretory products from the seminal vesicles and prostate crucial for sperm motility, sperm viability, and chromatin stability of the sperm [6], but that they are also important for semen liquefaction.

Tissue kallikrein-related peptidases, or KLKs, are members of a serine protease family that exhibit trypsin- and chymotrypsin-like activities. Of the 37 \( Klk \) genes in the mouse genome, 26 encode functional proteins [7]. KLKs are translated as pre-pro-KLKs and are regulated by a proteolytic activation cascade that produces active KLKs, which are secreted from the kidneys, liver, salivary glands, and male and female reproductive organs [8, 9]. Sperm in the ejaculate are entrapped in a seminal coagulum, which is comprised mainly of semenogelins (SEMGs), fibronectin, and collagen secreted from the seminal vesicles [10, 11]. Liquefaction is mainly modulated by prostate derived KLK3 [10]. In females, KLKs 5–8, 10–11, and 13–15 are expressed at very high levels in the cervix and vagina compared to in other adult tissues [12, 13]. Moreover, KLK1 and KLK3 transcripts are expressed at the highest level in human endometrium when circulating estradiol (E\(_2\)) is elevated [14, 15]. In rodents, E\(_2\) increases \( KLK \) expression in the uterus [16, 17]. These findings suggest that KLKs are expressed in the human and mouse reproductive tracts and that some of the KLKs in the uteri are regulated by E\(_2\). However, the role of the female reproductive tract in regulation of post-ejaculated seminal KLKs remains unclear.

E\(_2\) is a steroid hormone secreted from the granulosa cells of the ovary. Estrogens exert their functions through estrogen receptor \( \alpha \) and \( \beta \) (ESR1 and ESR2). ESR1 is predominantly expressed in the female reproductive tissues, which include the ovary, oviduct, uterus, and mammary gland [18]. We previously reported that mice lacking ESR1 in the epithelial cells (using \( Esr1^{fl}\) crossed with \( Wnt7a^{Cre}\) mice) are infertile [19], partly due to a reduction in the number of sperm able to reach the oviduct [20]. However, the effect of ESR1 loss in the epithelial cells on sperm transport in the uterus has not yet been investigated.
In this study, we showed 1) the expression of KLKS in the mouse uterus is downstream of E\textsubscript{2} signaling acting through epithelial ESR1, and 2) loss of epithelial ESR1 disrupts sperm transport by affecting semen liquefaction and sperm motility. Additionally, as the semen is deposited at the ectocervix in humans, we examined whether human ectocervical cells express KLK transcripts and whether this expression is modulated by E\textsubscript{2}. Our studies provide the first evidence of how the interplay between semen and the female reproductive tract could impact fertility.

**Results**

**Loss of ESR1 in uterine epithelial cells leads to a semen liquefaction defect in female mice**

Our previous findings demonstrated that loss of ESR1 in the mouse uterine and oviductal epithelial cells causes a reduction of the number of sperm in the oviduct [20], however, the cause of this sperm reduction is unknown. Therefore, we evaluated the uterine morphology of these uteri, regardless of a lack of ballooning in controls (Fig 1C). In addition, total fluid volume from the uterine lumen was significantly lower in E\textsubscript{sr1}\textsuperscript{f/f} females using immunohistochemical (IHC) analysis (Fig 1A). Gross morphology of E\textsubscript{sr1}\textsuperscript{f/f} uteri collected at approximately 8 h after mating showed ballooning uteri, however, Wnt7a\textsuperscript{Cre/+};Esr1\textsuperscript{f/f} uteri did not (Fig 1B). As a result, the uterine diameter of Wnt7a\textsuperscript{Cre/+};Esr1\textsuperscript{f/f} animals was significantly smaller than those of E\textsubscript{sr1}\textsuperscript{f/f} controls (Fig 1C). In addition, total fluid volume from the uterine lumen was significantly lower in Wnt7a\textsuperscript{Cre/+};Esr1\textsuperscript{f/f} than in E\textsubscript{sr1}\textsuperscript{f/f} animals (Fig 1D).

Astwood demonstrated that E\textsubscript{2} increases fluid accumulation in the uterine lumen and this E\textsubscript{2}-induced water imbibition is regulated through aquaporin (AQP) water channels [21, 22]. Our microarray analysis showed that E\textsubscript{2} treatment robustly increased the expression of Aqp1, Aqp5, and Aqp8 transcripts at 2 h, however, at 24 h, the induction of Aqp transcripts was not as strong as the 2 h treatment in the control uteri (S1 Table). These Aqp genes were expressed at significantly lower levels in Wnt7a\textsuperscript{Cre/+};Esr1\textsuperscript{f/f} compared to E\textsubscript{sr1}\textsuperscript{f/f} uteri 2 h or 24 h after E\textsubscript{2} treatment, except Aqp5 at 24 h (S1 Table). To determine whether Aqps were aberrantly expressed in Wnt7a\textsuperscript{Cre/+};Esr1\textsuperscript{f/f} at 8 h after mating, we collected uterine samples and performed real time RT-PCR analysis and found that the expression of the highly expressed Aqps in the uterus, including Aqp1, Aqp5, Aqp8, and Aqp11, were detected at comparable levels between E\textsubscript{sr1}\textsuperscript{f/f} and Wnt7a\textsuperscript{Cre/+};Esr1\textsuperscript{f/f} uteri at 0.5 dpc (Fig 1E). These findings suggest the water imbibition was rapidly mediated by E\textsubscript{2} through an up-regulation of Aqps in control uteri. However, at 8 h after mating, transcript levels of Aqps were not differentially expressed in E\textsubscript{sr1}\textsuperscript{f/f} and Wnt7a\textsuperscript{Cre/+};Esr1\textsuperscript{f/f} uteri, regardless of a lack of ballooning in Wnt7a\textsuperscript{Cre/+};Esr1\textsuperscript{f/f} uteri.

Strikingly, semen liquefaction is affected by a lack of uterine epithelial ESR1. The liquefaction time was determined by the time it took for semen collected from Esr1\textsuperscript{f/f} and Wnt7a\textsuperscript{Cre/+};Esr1\textsuperscript{f/f} uteri to fill a 25-μL capillary tube. In Esr1\textsuperscript{f/f} uteri, the semen liquefaction time was 1.86 ±0.15 min, whereas the semen collected from Wnt7a\textsuperscript{Cre/+};Esr1\textsuperscript{f/f} uteri was too viscous and could not fill the tube by the end of the 1 h experimental time (Fig 1F). This evidence is the first illustration that semen from a WT male can be solidified as a result of exposure to the Wnt7a\textsuperscript{Cre/+};Esr1\textsuperscript{f/f} female reproductive tract, which could likely lead to the severely reduced sperm number in the oviduct observed in our previous findings [20].

Histological analysis of uterine cross-sections demonstrated that the semen present in the Esr1\textsuperscript{f/f} uterine lumen appears loose, whereas dense materials were observed only in the
Wnt7aCre/+;Esr1f/f uteri (Fig 1G). The sperm density was measured to evaluate if the viscous semen or the dense materials within the Wnt7aCre/+;Esr1f/f uterine lumen contribute to the sperm entrapment/blockade within the uterus. We found the density of sperm/mm$^2$ in the...
Wnt7a<sup>Cre/+;</sup>Esr1<sup>iΔf</sup> uteri was significantly higher in comparison to the sperm present in the Esr1<sup>iΔf</sup> uteri (Fig 1H). Because the sperm density was higher in the Wnt7a<sup>Cre/+;</sup>Esr1<sup>iΔf</sup> uteri, we assessed whether the total sperm count per seminal volume was different in Esr1<sup>iΔf</sup> and Wnt7a<sup>Cre/+;</sup>Esr1<sup>iΔf</sup> uteri. We found there was no significant difference in total sperm count between Wnt7a<sup>Cre/+;</sup>Esr1<sup>iΔf</sup> and Esr1<sup>iΔf</sup> animals 8 h after mating (Fig 1I). To determine whether the sperm present in the uteri were motile, we counted the percentage of motile sperm per microscopic field and found that the sperm collected from Wnt7a<sup>Cre/+;</sup>Esr1<sup>iΔf</sup> uteri had significantly higher numbers of immotile sperm compared to those from Esr1<sup>iΔf</sup> uteri (Fig 1J; S1 and S2 Videos). Conversely, a significantly smaller percentage of sperm with rapid progressive motility was observed in the semen collected from Wnt7a<sup>Cre/+;</sup>Esr1<sup>iΔf</sup> compared to those from Esr1<sup>iΔf</sup> uteri. This finding suggests that in the absence of uterine epithelial ESR1, normal sperm were unable to dislodge from the seminal coagulum, leading to a decreased number of motile sperm.

**Semen coagulants in the uterus in the absence of epithelial ESR1 are not degraded**

Degradation of semen coagulants such as collagen and SEMG1 leads to liquefaction [10, 11]. To determine whether the liquefaction defect observed in Wnt7a<sup>Cre/+;</sup>Esr1<sup>iΔf</sup> uteri was due to defective degradation of semen coagulants, we evaluated the presence of collagen and SEMG1 within the uterus after mating. Using Masson’s Trichrome staining, the results indicated that material present in the uterine lumen of Wnt7a<sup>Cre/+;</sup>Esr1<sup>iΔf</sup> animals contained a considerable amount of collagen compared to Esr1<sup>iΔf</sup> animals (Fig 2A). Additionally, measurable levels of cleaved SEMG1 were present only in the Esr1<sup>iΔf</sup> animals, and were not detected in Wnt7a<sup>Cre/+;</sup>Esr1<sup>iΔf</sup> animals (Fig 2B and 2C). This suggests that lacking uterine epithelial ESR1 contributes to a liquefaction defect due to reduced semen coagulant degradation.

**Uterine Klk transcripts are regulated by E<sub>2</sub> signaling through epithelial ESR1**

In humans, it is known that KLK3 secreted from male accessory sex organs regulates semen liquefaction [10, 23]. However, we have reported here that liquefaction could also be modulated by the female reproductive tract. To elucidate whether the Klk family is present in the uterus and the expression is regulated by E<sub>2</sub> signaling, our previously published microarray dataset of the uteri from Esr1<sup>iΔf</sup> and Wnt7a<sup>Cre/+;</sup>Esr1<sup>iΔf</sup> animals treated with E<sub>2</sub> for 2 h [24] was analyzed. Transcript levels of the Klk1 and Klk1b families were increased in E<sub>2</sub> treated Esr1<sup>iΔf</sup> uteri at 2 h compared to vehicle treatment (Fig 3A). However, these E<sub>2</sub>-induced Klk1 and Klk1b family expressions were minimally detected or were not at a detectable level in Wnt7a<sup>Cre/+;</sup>Esr1<sup>iΔf</sup> uteri compared to vehicle treatment. To validate expression at the transcriptional level in the presence of male ejaculates at 0.5 dpc, the mRNA expression of Klk1 and Klk1b5 was determined, as these two genes were abundant among other Klk1 family members. Klk1 and Klk1b5 expression was significantly reduced in Wnt7a<sup>Cre/+;</sup>Esr1<sup>iΔf</sup> uteri compared to Esr1<sup>iΔf</sup> uteri (Fig 3B). Moreover, we found that the KLK1B5 protein level was significantly lower in the Wnt7a<sup>Cre/+;</sup>Esr1<sup>iΔf</sup> uteri compared to Esr1<sup>iΔf</sup> uteri at 0.5 dpc (Fig 3C and 3D).

**Decreased uterine Klk mRNA levels are not due to a lack of epithelial cell proliferation**

It has been previously shown that Klk1 mRNA is expressed in the endometrial glands of humans and mice [15, 17]. Therefore, glandular epithelial cells may be the potential source of
KLK production in the uterine tissues. To determine whether the loss of uterine epithelial ESR1 affects cell proliferation and subsequently disrupts the Klk transcript levels, we evaluated the proliferation of all uterine cell types including luminal, glandular, and stromal cells at 0.5 dpc in Esr1<sup>f/f</sup> and Wnt7a<sup>Cre/+;Esr1<sup>f/f</sup></sup> animals. Ki67 was used as a marker to visualize cell proliferation. The percentages of Ki67 positive luminal epithelial and stromal cells were comparable between Esr1<sup>f/f</sup> and Wnt7a<sup>Cre/+;Esr1<sup>f/f</sup></sup> uteri (Fig 4A and 4B). However, Ki67 positive glandular epithelial cells were detected at a significantly higher level in Wnt7a<sup>Cre/+;Esr1<sup>f/f</sup></sup> than those of Esr1<sup>f/f</sup> uteri (Fig 4B). Additionally, the marker of the gland, Foxa2, was expressed at a significantly higher level in Wnt7a<sup>Cre/+;Esr1<sup>f/f</sup></sup> compared to Esr1<sup>f/f</sup> uteri (Fig 4C). These results suggest that a lack of Klk transcripts in the absence of epithelial ESR1 was not due to a loss of glandular epithelial cells; in fact, the marker of glandular epithelial cells was expressed at a higher level in uteri lacking epithelial ESR1.
Lacking epithelial ESR1 leads to increased serine protease inhibitor transcripts, but not SERPINH1 protein

Human KLK activity can be effectively inhibited by endogenous protease inhibitors such as serine protease inhibitors (SERPINs), serine protease inhibitors, Kazal type (SPINKs), elafin, and α1-antitrypsin [25, 26]. It has been previously shown that SERPIN inhibits KLK activity by interacting with the reactive loop, causing an irreversible protein conformational change of KLK [27, 28]. In addition, changes in expression levels of other proteinases and protease inhibitors could also affect KLK activity. Therefore, to explore whether the liquefaction defect observed in Wnt7aCre/+;Esr1f/f uteri was due to aberrant expression of protease inhibitors, proteinases, and proteinase inhibitors, in addition to a loss of Klk production, the microarray dataset of E2 treated Esr1f/f and Wnt7aCre/+;Esr1f/f uteri was assessed (Table 1). To compare the expression level of proteases and protease inhibitors, we listed the signal intensities of genes relative to Esr1 in Table 1. Esr2 was used as a negative control. We found that 7 of 22 Serpin gene family members had higher signal intensities, whereas the intensities of 3 of 22 Serpins were lower in Wnt7aCre/+;Esr1f/f compared to Esr1f/f uteri (Table 1). However, 54% (12 of 22) of the Serpin genes in Wnt7aCre/+;Esr1f/f were expressed at comparable levels to those of Esr1f/f uteri. In addition, we evaluated the expression of other proteinases and proteinase inhibitors such as Spinks, matrix metalloprotenases (Mmps), tissue inhibitor of metalloproteinases (Timp), cysteine proteinases and protease inhibitors, which include defensins (Def), cathepsins (Cts), α2-macroglobulin (A2m), and secretory leukocyte peptidase inhibitor (Slpi). The

Fig 3. Uterine expression profile of Klk transcripts using microarray analysis. A. Esr1f/f and Wnt7aCre/+;Esr1f/f females were ovariectomized and treated with E2 at 0.25 μg/mouse for 2 h. Expression values indicate raw intensities in E2 treated tissues in both Esr1f/f and Wnt7aCre/+;Esr1f/f uteri (n = 3 mice/genotype/treatment). Expression level of Esr1 was used as a reference to compare the overall gene expression level. B. Expressions of Klk1 and Klk1b5 were validated using real-time PCR from the uterine tissues collected at 0.5 dpc (n = 4–5 mice/genotype). C. Protein expression of Klk1B5 in the uteri of Esr1f/f and Wnt7aCre/+;Esr1f/f animals at 0.5 dpc shown by immunoblotting. β-Actin was used as a loading control (n = 3–4 mice/genotype). D. Quantitative analysis of Klk1B5 protein expression normalized to β-Actin. *, ***p<0.05, 0.001; significant difference between Esr1f/f and Wnt7aCre/+;Esr1f/f animals, unpaired t-test. Graphs represent mean±SEM.

https://doi.org/10.1371/journal.pgen.1006743.g003
expression levels of these proteases and protease inhibitors were at comparable levels between E2-treated Wnt7a Cre/+; Esr1 \textit{f/f} and E2-treated Esr1 \textit{f/f} uteri (Table 1). The only exceptions were the expression of Def3 was significantly lower and Ctsw was significantly higher in E2-treated Wnt7a Cre/+; Esr1 \textit{f/f} compared to E2-treated Esr1 \textit{f/f} uteri.

To identify whether these genes were expressed and regulated by epithelial ESR1 during early pregnancy, we collected the uterine tissues at 0.5 dpc from Esr1 \textit{f/f} and Wnt7a Cre/+; Esr1 \textit{f/f} animals and evaluated the expression levels using real-time PCR analysis. Serpina1b, Serpina1d, Serpinb7, Serpinh1, Spink3, Mmp2, Mmp9, Mmp11, Mmp14, Mmp17, Timp1, Timp2, and Timp3 genes were selected for real-time PCR analysis based on their moderate to high levels of signal intensities (from the microarray dataset mentioned in the previous section) compared to other genes in the families. We found that Serpina1b, Serpina1d, and Spink3 were expressed at comparable level between Esr1 \textit{f/f} and Wnt7a Cre/+; Esr1 \textit{f/f} uteri at 0.5 dpc (Fig 5A). However, expression of Serpinb7 and Serpinh1 were significantly higher in Wnt7a Cre/+; Esr1 \textit{f/f} compared to Esr1 \textit{f/f} uteri (Fig 5A). We evaluated the protein expression of the most abundant uterine SERPIN, SERPINH1, using immunoblotting and found that although the transcription level of Serpinh1 was significantly higher in Wnt7a Cre/+; Esr1 \textit{f/f} compared to Esr1 \textit{f/f} uteri, the translation
Table 1. Microarray analysis showing all the transcript levels of proteases, proteinases, and their inhibitors detected in the uterus of Esr1<sup>f/f</sup> and Wnt7a<sup>Cre<sup>+</sup></sup>;Esr1<sup>f/f</sup> 2 h after E<sub>2</sub> treatment.

| Accession # | Primary Sequence Name | Esr1<sup>f/f</sup> E<sub>2</sub> 2h | Wnt7a<sup>Cre<sup>+</sup></sup>;Esr1<sup>f/f</sup> E<sub>2</sub> 2h | Fold Change |
|-------------|-----------------------|-------------------------------|----------------------------------|-------------|
|             |                       | Signal intensity | p-value | Signal intensity | p-value |                                     |
| **Estrogen Receptors (Esr)** | | | | | |
| NM_007956  | Esr1                  | 63,423.7          | 0.0E-00 | 16,143.2         | 3.3E-08 | -3.9                                   |
| NM_207707  | Esr2                  | 10.6              | 9.0E-05 | 14.8             | 2.0E-04 | 1.4                                    |
| **Serine protease inhibitors (Serpin)** | | | | | |
| NM_009244  | Serpina1b             | 190.4             | 1.1E-09 | 1,359.7          | 2.6E-23 | 7.1                                    |
| NM_009246  | Serpina1d             | 7,489.0           | 5.7E-07 | 34,335.3         | 3.0E-19 | 4.6                                    |
| NM_009247  | Serpina1e             | 167.7             | 7.9E-11 | 1,096.1          | 0.0E-00 | 6.5                                    |
| M64085     | Serpina3g             | 1,609.0           | 1.7E-11 | 2,174.6          | 0.0E-00 | 1.4                                    |
| NM_009253  | Serpina3m             | 449.2             | 2.2E-11 | 239.9            | 3.3E-12 | -1.9                                   |
| NM_009252  | Serpina3n             | 272.4             | 5.3E-06 | 280.6            | 2.0E-05 | 1.0                                    |
| NM_198028  | Serpinb10-ps*         | 146.0             | 9.2E-11 | 1,338.9          | 2.1E-02 | 9.2                                    |
| NM_025867  | Serpinb11             | 8,716.5           | 5.6E-09 | 16,176.9         | 6.6E-03 | 1.9                                    |
| NM_025429  | Serpinb1a             | 7,391.3           | 1.1E-31 | 9,023.8          | 0.0E-00 | 1.2                                    |
| NM_173051  | Serpinb1c             | 911.1             | 1.0E-01 | 801.1            | 0.0E-00 | -1.1                                   |
| NM_009254  | Serpinb6a             | 17,304.3          | 1.0E-11 | 15,181.6         | 0.0E-00 | -1.1                                   |
| NM_011454  | Serpinb6b             | 5,768             | 0.0E-00 | 4,993.1          | 0.0E-00 | -1.2                                   |
| NM_148942  | Serpinb6c             | 1,276.8           | 0.0E-00 | 790.3            | 2.2E-31 | -1.6                                   |
| NM_027548  | Serpinb7              | 469.5             | 0.0E-00 | 5,919.6          | 6.7E-03 | 12.6                                   |
| NM_011459  | Serpinb8              | 223.3             | 1.3E-16 | 437.6            | 3.5E-12 | 2.0                                    |
| NM_009256  | Serpinb9              | 765.9             | 2.5E-14 | 825.8            | 8.8E-08 | 1.1                                    |
| NM_008871  | Serpine1              | 2,212.4           | 6.0E-29 | 1,959.2          | 4.6E-17 | -1.1                                   |
| AK046232   | Serpine2              | 1,211.3           | 9.5E-12 | 935.3            | 1.7E-29 | -1.2                                   |
| NM_011340  | Serpinf1              | 44,423.2          | 0.0E-00 | 40,099.5         | 0.0E-00 | -1.1                                   |
| NM_008878  | Serpinf2              | 108.0             | 0.0E-00 | 102.9            | 1.2E-11 | -1.0                                   |
| NM_009776  | Serping1              | 25,991.3          | 5.9E-03 | 33,053.9         | 0.0E-00 | 1.3                                    |
| NM_009825  | Serpinh1              | 228,658.0         | 0.0E-00 | 136,746.8        | 0.0E-00 | -1.7                                   |
| **Serine Protease Inhibitors, Kazal Type (Spink)** | | | | | |
| NM_183284  | Spink2                | 66.0              | 9.3E-31 | 250.6            | 3.1E-09 | 3.8                                    |
| NM_009258  | Spink3                | 9,864.3           | 0.0E-00 | 8,934.6          | 0.0E-00 | -1.1                                   |
| NM_183136  | Spink8                | 540.3             | 2.3E-03 | 515.4            | 1.2E-06 | -1.0                                   |
| NM_030061  | Spink12               | 154.1             | 3.9E-07 | 139.6            | 1.0E-05 | -1.1                                   |
| **Matrix Metalloproteinases (Mmp)** | | | | | |
| NM_008610  | Mmp2                  | 22,720.9          | 0.0E-00 | 27,531.3         | 0.0E-00 | 1.2                                    |
| NM_010809  | Mmp3                  | 2,191.8           | 2.4E-04 | 2,764.3          | 0.0E-00 | 1.3                                    |
| NM_010810  | Mmp7                  | 146.1             | 1.4E-15 | 342.0            | 4.0E-14 | 2.3                                    |
| NM_008611  | Mmp8                  | 35.4              | 1.4E-02 | 124.7            | 2.3E-02 | 3.5                                    |
| NM_013599  | Mmp9                  | 584.6             | 2.6E-12 | 678.0            | 1.3E-25 | 1.2                                    |
| NM_019471  | Mmp10                 | 846.8             | 3.8E-20 | 457.8            | 2.4E-06 | -1.8                                   |
| NM_008606  | Mmp11                 | 15,894.3          | 4.3E-13 | 26,041.9         | 1.0E-05 | 1.6                                    |
| NM_008605  | Mmp12                 | 636.8             | 3.2E-03 | 896.6            | 1.0E-04 | 1.4                                    |
| NM_008607  | Mmp13                 | 14.6              | 4.7E-03 | 10.5             | 1.7E-02 | -1.4                                   |
| NM_008608  | Mmp14                 | 55,741.3          | 6.4E-15 | 67,370.4         | 2.0E-22 | 1.2                                    |
| NM_008609  | Mmp15                 | 740.4             | 3.6E-22 | 1,771.6          | 1.6E-17 | 2.4                                    |
| AK034828   | Mmp16                 | 1,256.7           | 0.0E-00 | 1,149.2          | 0.0E-00 | -1.1                                   |
| NM_011846  | Mmp17                 | 18,790.8          | 1.9E-13 | 9,951.8          | 7.7E-08 | -1.9                                   |

(Continued)
of SERPINH1 was at comparable levels (Fig 5B and 5C). In addition, only Mmp2, not other Mmps nor Timps, was expressed at a significantly higher level in Wnt7aCre+;Esr1ff uteri (Fig 5D and 5E). These results suggest that E2 not only regulates the expression of Klk transcripts, but that it also regulates the transcription of serine protease inhibitors (Serpinb7 and Serpinh1). However, SERPINH1 protein level was not altered in the absence of uterine epithelial ESR1.

To explore the possibility that alteration of KLK activity in the uteri can disrupt the post-ejaculated semen liquefaction process, we injected into the uterine lumen a tissue KLK inhibitor (4-(2-Aminoethyl)benzenesulfonyl fluoride hydrochloride or AEBSF) to inhibit serine proteases including multiple tissues’ KLKs [29]. Note that KLKs in the uterus of a mated female

Table 1. (Continued)

| Accession # | Primary Sequence Name | Esr1ff E2 2h | Wnt7aCre+;Esr1ff E2 2h | Fold Change |
|-------------|----------------------|--------------|------------------------|-------------|
| NM_021412   | Mmp19                | 1,237.7      | 976.1                  | -1.3        |
| NM_013903   | Mmp20                | 3.6          | 2.6                    | -1.4        |
| NM_152944   | Mmp21                | 11.6         | 8.5                    | -1.4        |
| NM_011985   | Mmp23                | 3,754.6      | 4,186.8                | 1.1         |
| NM_010808   | Mmp24                | 113.1        | 63.4                   | 1.0E-11     |
| NM_011593   | Timp1                | 2,404.3      | 2,775.3                | 1.6E-08     |
| NM_011594   | Timp2                | 125,039.8    | 175,180.4              | 7.6E-24     |
| NM_011595   | Timp3                | 132,754.1    | 118,598.0              | -1.1        |
| NM_080639   | Timp4                | 254.3        | 156.7                  | -1.6        |

| Tissue Inhibitor of Metalloproteinases (Timp) |
|-----------------------------------------------|
| NM_007850 | Defa3      | 12,116.57 | 1,945.88 | 2.4E-39 | -6.2 |
| NM_14517  | Defb19     | 116.50    | 98.33    | 0.0E+00 | -1.2 |
| NM_008906 | Ctsa       | 16,859.07 | 23,719.12| 0.0E+00 | 1.4  |
| NM_007979 | Ctsb       | 206,338.64| 140,848.03| 0.0E+00| -1.2 |
| NM_009982 | Ctsc       | 6,017.71  | 6,358.88 | 1.1E-17 | 1.1  |
| NM_009983 | Ctsd       | 72,181.23 | 98,438.81| 2.8E-45 | 1.4  |
| NM_007979 | Ctse       | 206.77    | 248.40   | 1.2E-15 | 1.2  |
| NM_019861 | Ctsf       | 5,795.26  | 8,056.69 | 9.6E-25 | 1.4  |
| NM_007801 | Ctsf       | 66,238.02 | 58,639.07| 0.0E+00 | -1.2 |
| NM_007802 | Ctsk       | 2,400.70  | 3,140.82 | 1.5E-28 | 1.3  |
| NM_009984 | Ctsl       | 143,215.02| 113,895.86| 0.0E+00| -1.3 |
| NM_177662 | Ctso       | 8,020.15  | 11,758.58| 0.0E+00 | 1.5  |
| NM_021281 | Ctsn       | 47,364.07 | 63,009.99| 7.7E-28 | 1.3  |
| NM_009985 | Ctsw       | 1,121.71  | 2,135.26 | 0.0E+00 | 1.9  |
| NM_022325 | Ctsz       | 36,867.16 | 27,974.15| 1.0E-05 | -1.3 |

| Other Cysteine Proteases: Cathepsin (Cts) and Defensins (Def) |
|-------------------------------------------------------------|
| NM_007850 | Defa3 | 12,116.57 | 1,945.88 | 2.4E-39 | -6.2 |
| NM_14517  | Defb19 | 116.50 | 98.33 | 0.0E+00 | -1.2 |
| NM_008906 | Ctsa | 16,859.07 | 23,719.12 | 0.0E+00 | 1.4 |
| NM_007979 | Ctsb | 206,338.64 | 140,848.03 | 0.0E+00 | -1.2 |
| NM_009982 | Ctsc | 6,017.71 | 6,358.88 | 1.1E-17 | 1.1 |
| NM_009983 | Ctsd | 72,181.23 | 98,438.81 | 2.8E-45 | 1.4 |
| NM_007979 | Ctse | 206.77 | 248.40 | 1.2E-15 | 1.2 |
| NM_019861 | Ctsf | 5,795.26 | 8,056.69 | 9.6E-25 | 1.4 |
| NM_007801 | Ctsf | 66,238.02 | 58,639.07 | 0.0E+00 | -1.2 |
| NM_007802 | Ctsk | 2,400.70 | 3,140.82 | 1.5E-28 | 1.3 |
| NM_009984 | Ctsl | 143,215.02 | 113,895.86 | 0.0E+00 | -1.3 |
| NM_177662 | Ctso | 8,020.15 | 11,758.58 | 0.0E+00 | 1.5 |
| NM_021281 | Ctsn | 47,364.07 | 63,009.99 | 7.7E-28 | 1.3 |
| NM_009985 | Ctsw | 1,121.71 | 2,135.26 | 0.0E+00 | 1.9 |
| NM_022325 | Ctsz | 36,867.16 | 27,974.15 | 1.0E-05 | -1.3 |

| Other Protease Inhibitors: α2-macroglobulin (A2m) and Secretory Leukocyte Peptidase Inhibitor (Spli) |
|---------------------------------------------------------------|
| NM_175628 | A2m | 264.6 | 304.7 | 5.3E-08 | 1.2 |
| NM_011414 | Slpi | 6,455.48 | 4,843.85 | 4.5E-42 | -1.3 |

† All the transcripts detected in each gene family in the uteri were listed in the table regardless of the fold changes. Transcript levels indicated by the raw signal intensities; cut off values were ≤ 100 in both groups.

/ Esr1 expression level was used to compare to the expression to other genes, Esr2 was used as a negative control, in which level of expression is less than the intensity of 100.

* pseudogene

https://doi.org/10.1371/journal.pgen.1006743.t001
could originate from both the semen and the female reproductive tract. Compared to the 
Wnt7aCre+/Esr1f/f uteri, which lack Klk transcripts, the AEBSF treatment stimulated a significant 
reduction in KLK activities without an alteration of other E2-targeted pathways. The uterine 
diameter as well as intrauterine fluid volume of semen collected from female mice treated 
with AEBSF were significantly reduced compared to those of saline treated mice (Fig 6A and 6B). 
However, we were unable to determine the liquefaction time of the semen collected from AEBSF 
treated animals, as the volume of semen was insufficient for measurement (Fig 6C). More impor-
tantly, the number of sperm that reached the oviducts was drastically decreased in the female 
mice treated with AEBSF compared to the saline treated controls (Fig 6D). In addition, we found 
that the SEMG2 protein tended to be expressed at a higher level in the AEBSF treated group, 
whereas the cleaved SEMG1 protein tended to be lower in the AEBSF compared to the saline 
treated group (Fig 6E and 6F). This finding indicates that the use of a pharmacological inhibitor
of serine protease activity (including KLKs) recapitulates the phenotype observed in Wnt7a^{Crem+}; Esr1^{f/f} uteri.

Human ectocervical and endocervical cells express KLKs

Due to anatomical differences in the location of semen after ejaculation between mice and humans, as well as the difference between human and mouse KLKs, we tested whether human cervical cells, particularly ectocervical (hEct1) and endocervical (hEnd1) cells, express KLKs and their inhibitors, SPINKs. We found that in the absence of hormonal treatment, KLK1 and KLK7 were expressed at minimal levels in hEct1 and hEnd1 cells (Fig 7A). As expected, prostate-specific KLKs (KLK2 and KLK3) were expressed only in the prostate cancer (LNCaP) cell line. hEct1 cells expressed KLK4, KLK5, and KLK8 at high levels relative to other KLKs. hEnd1 cells also expressed KLK4 and KLK5, but at lower levels, and showed a slightly higher level of KLK8 compared to hEct1 cells. SPINK5 and SPINK6 were expressed in hEct1 cells. However, hEnd1 cells only expressed SPINK5, and not SPINK6. In addition, KLK15 was expressed only in the LNCaP cells. Ishikawa (endometrial cancer) cells were used as a negative control.

hEct1 cells were chosen to assess whether E \textsubscript{2} regulates the expression of KLKs and SPINKs based on their anatomical location, as they are the first cells semen comes in contact with after ejaculation. First, we identified whether hEct1 cells expressed ESR1 in comparison to other cell types using RT-PCR. The transcript level of ESR1 was approximately 15-fold higher in hEct1 cells compared to hEnd1 and LNCaP cell lines, and ESR1 expression in Ishikawa cells...
remained below the detection threshold (Fig 7B). Protein levels of ESR1 were confirmed using immunoblotting (Fig 7C). The low level of β-ACTIN in the LNCaP cell line is likely due to the nature of LNCaP cells, which do not tightly adhere to the culture dish, and thus require fewer actin filaments.

After confirming the presence of ESR1 in hEct1 cells, hEct1 cells were treated with E$_2$ in the presence or absence of ICI 182,780 (ICI; ESR antagonist) to inhibit the action of ESR1. E$_2$ at a dose of 10 nM significantly increased the expressions of KLK4, KLK5, KLK8, SPINK5, and SPINK6 (Fig 7D). In the presence of ICI, E$_2$-induced expression of those genes was completely abolished (Fig 7D). Collectively, these results indicate that human cervical cells expressed distinct family members of KLKs compared to those in prostate cells, and the expression of KLKs and their inhibitors in ectocervical cells was regulated through E$_2$/ESR1 action.

We propose a network of pathways to explain our observations of the process of semen liquefaction in the female reproductive tract (Fig 8). When semen, which contains KLKs, enters the uterus, it is exposed to uterine KLKs and KLK inhibitors that have been produced in response to E$_2$ stimulation of ESR1. Normally, total KLK enzymatic activity overwhelms inhibitory action and produces liquefaction of the semen, which frees the sperm to swim into the oviduct. In addition, E$_2$/ESR1 signaling may upregulate Aqp genes to increase fluidity of uterine contents and further support sperm movement into the oviduct. This proposed network should guide future exploration of the processes of liquefaction of semen and release of sperm to ascend to the site of fertilization.

**Discussion**

In this study we evaluated the role of uterine epithelial ESR1 during semen liquefaction in the female reproductive tract to produce the following major findings: 1) E$_2$ through ESR1 plays a
crucial role in mammalian females by regulating semen coagulation and liquefaction and 2) KLKs and their inhibitors in human ectocervical cells are regulated by E2 in an ESR1-dependent manner.

E2 signals in the female reproductive tract and semen liquefaction defect

Previous studies illustrated that female mice lacking ESR1 in the uterine and oviductal epithelial cells show a severely reduced number of sperm in the oviduct [20], however, the cause of this decrease was unclear. After ejaculation, sperm need to be dislodged from the seminal coagulum prior to traveling into the oviduct. In humans, semen from fertile men is completely liquefied after 20 to 30 minutes post-ejaculation in vitro [30]. It is known that liquefaction defects such as semen hyperviscosity is one of the causes of infertility in men [31], however, defective liquefaction caused by female conditions has never been reported. After ejaculation, semen is exposed to secretory proteins in the female reproductive tract, which possess a dynamic range of enzymatic activities including SPINKs [25]. Herein, we observed a liquefaction defect in Wnt7a\textsuperscript{Cre+};
Esr1<sup>f/f</sup> uteri when these females mated with a male proven breeder, indicating that liquefaction can be modulated and disrupted by an exposure to a suboptimal environment in the female reproductive tract. Therefore, we proposed that these complex enzymatic activities in the female reproductive tract can disrupt post-ejaculated semen liquefaction. Our findings suggest that a lack of E<sub>2</sub> signaling in the epithelial cells of the female reproductive tract causes faulty liquefaction and results in a fertility defect.

Intrauterine fluid accumulation and Aqp gene expression

Due to a difference in uterine morphology between Esr1<sup>f/f</sup> and Wnt7a<sup>Cre/+</sup>;Esr1<sup>f/f</sup> females after mating, we investigated possible pathways that could lead to a lack of uterine ballooning or imbition. One likely mechanism is E<sub>2</sub>-induced water transport channel activation. Astwood showed that luminal fluid volume is increased after 6 h of E<sub>2</sub> treatment [21]. Later, Zhang et al. demonstrated that this E<sub>2</sub>-induced fluid accumulation is due to regulation through AQP5 and AQP8 by using Aqp<sup>5−/−</sup> and Aqp<sup>8−/−</sup> mouse models [22]. Analysis of our microarray data on the aquaporin gene family showed that E<sub>2</sub> robustly induced the expression of Aqp<sup>1</sup>, Aqp<sup>5</sup>, and Aqp<sup>8</sup> 2 h after treatment in the uteri of ovariectomized control mice, and the effect declined 24 h after E<sub>2</sub> treatment. However, these robust E<sub>2</sub>-induced Aqp<sup>1</sup>, Aqp<sup>5</sup>, and Aqp<sup>8</sup> transcripts were not observed in the absence of uterine epithelial ESR1. We did not observe differential expression of Aqp transcripts in the Wnt7a<sup>Cre/+</sup>;Esr1<sup>f/f</sup> uterus after mating compared to controls. This is likely because the expression of Aqps had already declined to basal levels as the circulating level of E<sub>2</sub> dropped after mating. These findings suggest that Aqp<sup>1</sup>, Aqp<sup>5</sup>, and Aqp<sup>8</sup> are upregulated by E<sub>2</sub>/ESR1 signaling. Zhang et al. demonstrated that Aqp<sup>5−/−</sup>;Aqp<sup>8−/−</sup> mice are capable of having 80% of embryo implantation sites compared to controls, regardless of the significant decrease of intrauterine fluid accumulation [22]. However, Zhang et al. did not directly evaluate whether the reduction of uterine fluid disrupts sperm motility. Thus, the loss of fluid flow due to reduced uterine fluid volume could also result in the sperm motility defect observed in Wnt7a<sup>Cre/+</sup>;Esr1<sup>f/f</sup> females.

Expression of KLKs in the female reproductive tract is modulated by E<sub>2</sub>

KLKs are a family of serine proteases secreted from epithelial cells that play a central role in extracellular matrix remodeling, inflammation, and regulation of blood flow. There is limited knowledge regarding the proteolytic activities of seminal proteins after deposition in the female reproductive tract [32], therefore, it is likely that undetermined interactions between seminal proteins and secretions from the female reproductive tract may contribute to the liquefaction defect observed in Wnt7a<sup>Cre/+</sup>;Esr1<sup>f/f</sup> female mice. In males, KLK2 and KLK3 transcripts are regulated by androgens; and androgen responsive elements (ARE) are present in the promoters of both KLK2 and 3 [33]. Conversely, KLK1 expression in mouse and rat uteri is influenced by E<sub>2</sub> [17]; and an estrogen responsive element (ERE) is found in the Klk1 promoter [34]. In humans, KLK levels in cervical and vaginal fluid are positively correlated with pregnancy and are possibly regulated by female steroid hormones [13].

As KLKs are secreted proteins, there is considerable overlap in the protein composition of fluids from the different parts of the female reproductive tract in both mice [35] and humans [25]. In mice, we demonstrated that mRNA levels of Klks and their inhibitors are differentially expressed in the uterus and oviducts [20, 24]. Similar to mice, different KLKs are expressed in different cell types along the epithelial lining of the reproductive tract in women [12]. The secretory protein levels of KLKs correlate with the expression of each KLK member along the reproductive tract [25]. These findings suggest that the differential regulation of KLK expression in
each region of the female reproductive tract also plays a crucial part in regulating local KLK activities.

Seminal KLKs inhabit a different environment from their site of secretion when they are deposited in the female reproductive tract. Our study showed that a lack of ESR1 in mouse uterine epithelial cells caused severely reduced expression of genes in the Klk family. However, our previous studies show that in the absence of epithelial ESR1 in the oviduct, expression of Klks is induced [20]. Therefore, these findings indicate that Klk expression in response to E2 is differentially regulated between the uterus and the oviducts. This novel finding suggests that E2-regulated Klk transcripts in the female reproductive tract are tightly regulated in a tissue-specific manner, and the induction of Klks through ESR1 in the uterus may be a mechanism for post-ejaculated semen liquefaction in the female reproductive tract. We speculate this differential regulation mechanism is used in part to locally regulate KLK activity.

**Klk mRNA expression and cell proliferation**

E2 mediates the cell proliferation processes that are pivotal for cellular growth and differentiation. In both humans and mice, E2 increases the proliferation of cells in the female reproductive tract [36, 37]. Our previous work elucidates that normal uterine epithelial and stromal cell proliferation during early pregnancy is dependent on epithelial ESR1 [24]. To distinguish whether a loss of Klk production in the Wnt7a\textsuperscript{Cre/+};Esr1\textsuperscript{flo/flo} mice compared to Esr1\textsuperscript{flo/flo} mice was due to a difference in epithelial cell growth and proliferation, we assessed the proliferative index. We found the percentage of positive Ki67 luminal epithelial and stromal cells was comparable between Esr1\textsuperscript{flo/flo} and Wnt7a\textsuperscript{Cre/+};Esr1\textsuperscript{flo/flo} animals. However, in Wnt7a\textsuperscript{Cre/+};Esr1\textsuperscript{flo/flo} uteri, glandular epithelial cells had a significantly higher percentage of Ki67 positive cells compared to Esr1\textsuperscript{flo/flo} uteri. Thus to indirectly validate the gland formation, we evaluated the expression of Foxa2, a glandular epithelial cell marker [38], and observed a higher level of Foxa2 expression in Wnt7a\textsuperscript{Cre/+};Esr1\textsuperscript{flo/flo} compared to Esr1\textsuperscript{flo/flo} uteri. We reasoned that elevated Foxa2 expression as well as the glandular epithelial cell proliferation in the absence of epithelial ESR1 were due to a compensation for the lack of glandular products/secretions that normally provide positive feedback to stimulate uterine gland development. The increase in cell proliferation of glandular epithelium does not promote the expression of the Klks in the mouse, and the change of Klk expression is not a secondary effect from cell proliferation due to a lack of ESR1.

**Other proteases and protease inhibitors in the female reproductive tract**

Matsuda et al. demonstrated that 30 min of proteinase inhibitor treatment causes a solidification of human semen and results in a sperm motility defect [39]. In addition, the serine protease inhibitor SPINK3 is capable of inhibiting protease activity in the mouse uterus [40]. These findings indicate that the presence of protease inhibitors can disrupt semen liquefaction by suppressing protease activities from the semen. Our study demonstrated that the lack of ESR1 in epithelial cells of the female reproductive tract significantly increases the expression of the serine protease inhibitors Serpinb7 and Serpinh1. However, the translational level of SERPINH1 protein was not different. Moreover, transgenic mice overexpressing Serpinb7 showed normal fertility [41]. Thus, it is unlikely that the liquefaction defect in Wnt7a\textsuperscript{Cre/+};Esr1\textsuperscript{flo/flo} mice was due to excess protease inhibitors. In addition to serine proteases, other proteases like MMPs are also capable of degrading extracellular matrix proteins. Although MMP proteins do not possess the catalytic triads required for proteolytic function in KLKs (His57, Asp102, and Ser195) [42], neutrophils bearing proMMP9 can be attracted by seminal plasma and their activities are elevated post-coitus in the female uterus [43]. In our model, all Mmp transcripts and their inhibitors were expressed at the same level between Esr1\textsuperscript{flo/flo} and Wnt7a\textsuperscript{Cre/+};Esr1\textsuperscript{flo/flo}.
uteri. The only exception was a higher level of \textit{Mmp2} in \textit{Wnt7a^Cre/+;Esr1^{flt}} compared to \textit{Esr1^{flt}} uteri. MMP2 targets gelatin, collagen IV, V, VII, X and XI, fibronectin, laminin, elastin, and aggrecan \cite{44}. Therefore, it is possible that the increased level of MMP2 transcripts was a response to the presence of an elevated collagen content (Fig 2A). Nevertheless, the elevated \textit{Mmp2} level fails to correct the faulty semen liquefaction in the absence of uterine epithelial ESR1.

In addition to MMPs and SERPINs, the female reproductive tract also expresses several other proteases and protease inhibitors such as cathepsins, defensins, and SPLI, as part of their innate immune response to bacterial and viral infection \cite{45}. Overall expression of these proteases and protease inhibitors was at comparable levels in \textit{Esr1^{flt}} and \textit{Wnt7a^{Cre/+};Esr1^{flt}} uteri. Minor changes in the transcripts for some of these genes did not alter our conclusion that a loss of \textit{E2} regulation in the uterine epithelial cells causes a disruption in \textit{Klk} transcript levels, but not other proteases or protease inhibitors.

We investigated whether inhibition of multiple KLK activities in the uterus could mimic the phenotype of \textit{Wnt7a^{Cre/+};Esr1^{flt}} animals using AEBSF, an irreversible serine protease inhibitor that also affects tissue KLKs. We found that AEBSF treatment resulted in a drastic decrease in the number of sperm that reached the oviduct. However, the cleavage of SEMG1 in AEBSF treated animals was not significantly different from saline treated controls. It is possible that AEBSF could have unintended effects in the female reproductive tract. This could include inhibition of other serine proteases such as chymotrypsin and trypsin, which are present in semen and the uterus. This inhibitory effect could suppress the degradation of collagen and disrupt liquefaction. Moreover, post-mating uterus also contain the seminal KLKs. The suppression of KLK activities using AEBSF cannot rule out that liquefaction and semenogelin and collagen cleavage are catalyzed by seminal KLKs. Nevertheless, several proteases and protease inhibitors were present in both \textit{Esr1^{flt}} and \textit{Wnt7a^{Cre/+};Esr1^{flt}} uteri, and the solidified semen was only observed in the condition where uterine \textit{Klks} were minimally expressed.

**Sperm entrapment and a lack of SEMG cleavage**

Histological analysis demonstrated a semen liquefaction defect of entrapped sperm within the semen coagulum in the uterus in the absence of epithelial ESR1. The denser semen resulted in a prolonged liquefaction time in \textit{Wnt7a^{Cre/+};Esr1^{flt}} animals. The majority of sperm entrapped in the solidified semen were immotile as they were unable to dislodge from the seminal coagulum and the higher sperm density in \textit{Wnt7a^{Cre/+};Esr1^{flt}} uteri was attributed to a reduced fluid volume in the uterus. There was no statistically significant difference between total sperm number in \textit{Wnt7a^{Cre/+};Esr1^{flt}} and \textit{Esr1^{flt}} uteri. We further identified that gel-forming proteins in the seminal plasma, SEMG1 and collagen, were not degraded in \textit{Wnt7a^{Cre/+};Esr1^{flt}} uteri. Collectively, these results indicate that ejaculated semen requires additional regulation in the female reproductive tract to lyse gel-forming proteins and allow effective liquefaction.

**Human ectocervical cells express KLKs and are regulated through ESR1**

In women, post-ejaculated semen is deposited at the anterior wall of vagina adjacent to the ectocervix. To explore whether KLKs are also expressed and regulated by \textit{E2}/ESR1 signaling in human cervical cells, we determined the expression pattern of all KLK family members using immortalized hEct1 and hEnd1 cells. The results indicated that KLKs were expressed in the hEct1 cells and that KLK4, KLK5, and KLK8 were the most abundant serine proteases. This finding is relevant to reproductive medicine as it was previously shown that KLK4, KLK5, and KLK8 are able to cleave fibronectin \cite{46}, another important protein that contributes to semen coagulation \cite{47}. KLK5 is also responsible for digestion of collagen and modification of mucin
to facilitate sperm transport [13, 25]. In addition, Pro-KLK2, 3, 7, 8, and 14 in the semen are activated by KLK5 [48], which is self-activated over time [9].

More importantly, this study indicates that KLK inhibitors SPINK5 and SPINK6 were highly expressed in the hEct1 cell line. E₂ increases KLK and SPINK expression through an ESR1-dependent pathway. SPINK5 specifically inhibits KLK5, KLK7, and KLK14 activity, and mutations in SPINK5 cause Netherton Syndrome, a severe skin disorder [49, 50]. The function of SPINK6 is less well-established [51]. Although human seminal fluid contains KLK2, 3, 4, 5, 8, 11, 12, 14, and 15 [52], the function of SPINKs in semen liquefaction is unclear. Inhibition of KLK5 by SPINK5 and 6 can prevent the activation of other KLKs in the semen. Ultimately, inhibition of KLK5 could potentially lead to two problems: 1) a failure to activate KLK2 and 3, preventing the degradation of SEMG and causing faulty semen liquefaction and sperm liberation, and 2) a defective cervical mucin remodeling, as KLK5 and 12 are responsible for cleavage of mucin 4 and 5B, the main cervical mucus proteins [25, 53] to guide the sperm to go through the cervix. These findings strongly suggest that human KLKs and KLK inhibitors from the female reproductive tract are indispensable for normal semen liquefaction and sperm transport.

Conclusion
This study demonstrated a novel interaction between semen and the microenvironment in the female reproductive tract. It uncovered a post-ejaculated semen liquefaction process that occurs inside the female reproductive tract, a topic that has not yet been explored. The conclusion of the experiments proposed that abnormal E₂ signaling in the female reproductive tract leads to a semen liquefaction defect associated with defective SEMG cleavage and sperm transport and may be a possible cause for some cases of infertility. We proposed the explanation that the semen liquefaction defect could be caused by diminished KLK activity in female mice, however, this hypothesis should first be tested in multiple Klk knockout mouse models. This discovery regarding post-ejaculated liquefaction is crucial for advancing the field of reproductive medicine and can lead to potential diagnostic tools for unexplained infertility cases and to developing a novel contraception technology to entrap sperm.

Materials and methods
Ethics statement
Animals were handled according to Washington State University (WSU) Animal Care and Use Committee guidelines and in compliance with WSU-approved animal protocols #4702 and 4735.

Animals and experimental procedures
Adult female mice (7 to 12 weeks old) with a selective deletion of ESR1 in the epithelial cells of the female reproductive tract (Wnt7a(cre)%;Esr1(fl/fl)) [19] and their control littermates (Esr1(fl/fl)) were used in the experiments. The genotyping of the animals was carried out as previously described [19]. The deletion of ESR1 was confirmed using IHC analysis (details described below). Female mice were singly housed and bred overnight with a wild-type (WT) C57B6/J male. If a copulatory plug was observed the next morning at 8 a.m., the female was designated as 0.5 days post coitus (dpc). For the microarray analysis, the animals were ovariectomized, randomly divided into groups, and treated with the vehicle control (sesame oil) or 17β-estradiol (E₂ at a dose of 0.25 μg/mouse) for 2 and 24 h as described previously [24]. Microarray data in this publication were deposited in NCBI’s Gene Expression Omnibus and are accessible.
through GEO Series accession number GSE23072 (WT samples) and GSE53812 (\(Wnt7a^{Cre/+}; Esr1^{f/f}\) samples). The differentially expressed genes and statistical analysis for the microarray dataset were analyzed using Partek Genomics Suite (version 6.6.1 Beta 6.11.1115, St. Louis, MO) as described previously [24].

At the time of tissue collection, animals were euthanized using \(CO_2\) asphyxiation with cervical dislocation. Uterine diameters were measured using a ruler before tissue dissection. Semen was collected from the uteri and liquefaction time was determined by recording the time used to fill a 25 \(\mu\)L capillary tube using an adapted method as previously reported [54]. One uterine horn from each animal was snap frozen and stored at -80˚C for RNA and protein extraction. Contralateral horns were fixed in 10% phosphate-buffered formalin for histological analysis.

Histological procedures, IHC staining, and quantitative analysis of Ki67 expression

Formalin-fixed uterine tissues were dehydrated and embedded in paraffin. The tissues were cross-sectioned at 5 microns and stained with hematoxylin and eosin (H&E) using a standard histological protocol. For IHC staining, paraffin sections were dehydrated and the antigen was retrieved using citrate buffer in the decloaking chamber (BioCare Medical, Concord, CA). Endogenous peroxidase activity was blocked using 3% \(H_2O_2\). The uterine sections were blocked with 10% normal horse serum (NHS) diluted in automation buffer (50 mM Tris, 20 mM NaCl, 0.05% Tween-20) for 1 h at room temperature, then incubated with the primary antibodies against ESR1 (1:200, # MA5-13191, ThermoFisher Scientific, Carlsbad, CA) or Ki67 (1:200, #550609, BD Pharminogen, San Jose, CA) in 10% NHS for 1 h at room temperature. Mouse IgG was used in place of primary antibodies for a negative control. The secondary antibody (1:1000 biotinylated horse anti-mouse, Vector Laboratories, Burlingame, CA) was applied to the sections for 30 min at room temperature. Vectastain RTU Elite and ImmPact kits (Vector Laboratories) were used according to the manufacturer's protocols to detect the positive signals. Tissues were counterstained with hematoxylin, dehydrated, and coverslipped with Permount. The presence of collagen in the uterine content was determined using Masson’s Trichrome staining kit. Blue staining indicates the presence of collagen and red indicates cytoplasm. Quantification of Ki67 IHC was determined using ImageJ version 2.0.0-rc-43/1.51e (imagej.nih.gov) with Cell Counter Tool Plugins as previously described [24]. Three images from each animal were captured using the Leica Application Suite (Leica Microsystems Inc., Buffalo Grove, IL). The number of Ki67 positive cells was counted and calculated as the percentage of positive cells per each cell type (luminal epithelial, glandular epithelial, and stromal cells) in each image.

Semen collection, sperm number, and sperm motility analysis

Semen was collected from the uteri of \(Esr1^{f/f}\) and \(Wnt7a^{Cre/+}; Esr1^{f/f}\) females approximately 8 h after mating. The female reproductive tract including the vagina was collected. The area between the uterus and cervix was cut open into a 1.5 mL microcentrifuge tube in order to collect the semen. The uterine horns were squeezed using toothless forceps from the ovarian end to the vaginal end to extract semen from the uterine lumen. The tubes were spun down briefly and the uterine fluid volume was determined. The semen was then diluted 1:200 in di\(H_2O\) and the number of sperm was counted using a hemocytometer. The total sperm number was calculated and normalized to the total fluid volume collected. Simultaneously, another 5 \(\mu\)L of fresh semen was dropped onto a glass slide and covered with a coverslip. Bright field video images of sperm motility were recorded with the 100x objective lens (4–8 different microscopic fields/
sample) using a DMi8 Leica Microscope (Leica Microsystems). The sperm motility within each microscopic field was sorted into four categories: immotile, non-progressive, slow progressive, and rapid progressive, and the percentage of sperm in each category was calculated. The total number of sperm evaluated was 339 for \textit{Esr1}^{f/f} and 414 for \textit{Wnt7a}^{Cre/+};\textit{Esr1}^{f/f} groups (\(n = 3\) females/genotype). The time between animal euthanasia and sperm video recording was within 5 min to preserve the maximal sperm viability.

**Sperm density**

The sperm density was determined from H&E stained tissues collected from 0.5 dpc uteri and observed with the 20x objective lens. The genotype of the animals was blinded from the observer. The number of sperm within the uterine lumen was counted manually using winDRP software (v1.6.4) [55], the total area was measured and used to calculate the sperm density per mm\(^2\). Data were collected from 7 \textit{Esr1}^{f/f} and 10 \textit{Wnt7a}^{Cre/+};\textit{Esr1}^{f/f} animals (1 image per animal).

**Intraluminal treatment of AEBSF**

Adult female C57BL6/J mice (7–12 weeks old) were used. The estrus stage of the estrous cycle was determined using a vaginal smear. At 5 p.m. on the determined day of estrus, females were administered 15 \(\mu\)L of saline pH 5.5 or 15 \(\mu\)L of AEBSF (4-(2-Aminoethyl)benzenesulfonyl fluoride hydrochloride, Amresco, Dallas, TX) at a dose of 300 \(\mu\)g/mouse through transcervical treatment using a Non Surgical Embryo Transfer (NSET) device [56]. The 300 \(\mu\)g dose of AEBSF was selected based on the demonstration of Sun \textit{et al.} that a single intraluminal injection effectively inhibits embryo-uterine implantation [57]. The females were immediately housed with a proven male breeder overnight. The next morning, presence of a copulatory plug was designated as 0.5 dpc. The animals were euthanized at 8 a.m. and the uteri were collected as described above. The oviducts were flushed with 100 \(\mu\)L of diH\(_2\)O onto the glass slide. The total number of sperm in the oviduct was counted manually under a brightfield microscope with the 20x objective lens.

**Gene expression analysis using RT-PCR**

RNA was extracted from the uteri or human cell lines using RiboZol ME Reagent (Amresco, Solon, OH) according to the manufacturer’s protocol. A total of 1 \(\mu\)g RNA was used as a template for the reverse transcriptase reaction according to the manufacturer’s protocol (qScript cDNA SuperMix, QuantaBio, Beverly, MA). The cDNA products were diluted at 1:10 in nuclease-free H\(_2\)O. Diluted cDNA (1 \(\mu\)L) was used as a template for the PCR reaction (PerfeCTa SYBR Green FastMix, QuantaBio) according to the manufacturer’s protocol. PCR reactions were run and raw data were recorded in a 7500 Fast Real-Time PCR System (Applied Biosystems, ThermoFisher). Expression values in uterine samples were calculated as fold change normalized to ribosomal protein L7 (\textit{Rpl7}) expression, relative to the vehicle or \textit{Esr1}^{f/f}. Expression of human \textit{KLKs}, \textit{SPINKs}, and \textit{ESR1} was calculated relative to \textit{RPL5} expression. The primer sequences used in the experiments are listed in S2 Table.

**Immunoblotting**

Protein was extracted from uterine tissues using T-PER tissue protein extraction reagent (ThermoFisher) with Halt protease and phosphatase inhibitors (ThermoFisher). The protein concentration was determined using a BCA protein assay (ThermoFisher). A total of 20 \(\mu\)g protein was loaded into each lane of a 10% acrylamide gel. The protein gels were transferred to
a nitrocellulose membrane using Trans-Blot Turbo (Bio-Rad Laboratories Inc., Hercules, CA). To visualize the equal protein loading and transfer, the membranes were incubated with 0.1% Ponceau S in 1% acetic acid. Membranes were then blocked with 5% non-fat dry milk in Tris-buffered saline with 0.1% tween-20 (TBST) for 1 h at room temperature. The membranes were then incubated with primary antibodies (1:1000 of KLK1B5 #MBS175442, MyBioSource, San Diego, CA; 1:1000 of SERPINH1 (or HSP47), # MAB9166, R&D Systems, Minneapolis, MN; 1:2000 of β-ACTIN #SC-47778, Santa Cruz Biotechnology, Inc., Dallas, TX; 1:1000 of SEMG1 #ab139405, Abcam, Cambridge, MA) in 5% milk TBST at 4˚C overnight. The secondary antibodies were incubated for 1 h at room temperature with a dilution of 1:5000 in 5% milk TBST. The blotting was detected using Amersham ECL Select (GE Healthcare Bio-Sciences, Pittsburgh, PA). The chemiluminescent signals were detected and images were captured using ChemiDoc MP System (Bio-Rad).

**Human cell cultures**

Immortalized human ectocervical (hEct1) and endocervical (hEnd1) cells were purchased from ATCC (Manassas, VA). Human endometrial cancer (Ishikawa) cells derived from the 3H12 clone [58] and human prostate cancer (LNCaP) cells (ATCC) were used as controls for the experiments. Immortalized hEct1 and hEnd1 cells were cultured in keratinocyteserum-free medium (ThermoFisher) with 0.1 ng/mL human recombinant epidermal growth factor, 0.05 mg/mL bovine pituitary extract, and 0.4 mM calcium chloride (complete KSFM) at 37˚C with 5% CO₂. Ishikawa and LNCaP cells were cultured in RPMI medium (Hyclone, South Logan, UT) supplemented with 10% fetal bovine serum (Gemini Bio-Products Inc., Woodland, CA), 100 U/mL penicillin, and 100 μg/mL streptomycin. Cells were cultured to 80–90% confluence, washed with phosphate buffered saline (PBS), and harvested using 0.25% trypsin-EDTA (Sigma, St. Louis, MO). RNA was extracted using RiboZol ME as described above.

For the analysis of endogenous gene expression in hEct1 cells in response to E₂, the cells were plated at a density of 1.33x10⁶ cells/mL in a 6-well plate containing complete KSFM media. Cells were grown to 80–90% confluence, then treated with vehicle (0.1% ethanol) or E₂ (1 and 10 nM) in the presence or absence of ICI 182,780 (ICI; 1 μM) for another 24 h. Cells were then harvested and RNA was extracted using RiboZol ME as indicated above.

**Statistical analysis**

Data are represented as mean±SEM and analyzed using GraphPad Prism version 6.0 for Mac OS X. Data were evaluated for statistically significant differences (p<0.05) using an unpaired student t-test, unless otherwise indicated.

**Supporting information**

S1 Video. Representative video recording of the semen freshly collected from control uteri approximately 8 h after mating at 1000x magnification with a speed of 12 frames/second (n = 3 females).

(SAVI)

S2 Video. Representative video recording of the semen freshly collected from Wnt7a<sup>Cre/+</sup>; Esr1<sup>ff</sup> uteri approximately 8 h after mating at 1000x magnification with a speed of 12 frames/second (n = 3 females).

(SAVI)

S1 Table. Microarray analysis showing all the transcript levels of aquaporins detected in the uterus of Esr1<sup>ff</sup> and Wnt7a<sup>Cre/+</sup>;Esr1<sup>ff</sup> female 2 h and 24 h after E<sub>2</sub> treatment. π All the
transcripts detected in the gene family in the uteri were listed in the table regardless of the fold changes. Transcript levels indicated by the raw signal intensities; cut off values were \( \leq 100 \) in both groups.

(DDCX)

**S2 Table. List of primer sequences\(^*\) used in this study.** \( \pi \) \( m \) and \( h \) prefixes refer to mouse and human primers, respectively.

(DDCX)

**Acknowledgments**

We thank Drs. Kenneth Korach (National Institute of Environmental Health Sciences; NIEHS) and Richard Behringer (University of Texas, MD Anderson Cancer Center) for \( \text{Esr1}^{\text{ff}} \) and \( \text{Wnt7a}^{\text{Cre/+}} \) mice, respectively, the NIEHS Histology Core for Masson’s Trichrome Staining, and Sydney Lierz (NIEHS) for critical reading of this manuscript.

**Author Contributions**

**Conceptualization:** SL WW.

**Data curation:** SL MG RLG WW.

**Formal analysis:** SL MG RLG WW.

**Funding acquisition:** WW.

**Investigation:** SL MG RLG WW.

**Methodology:** SL WW.

**Project administration:** WW.

**Software:** SL.

**Supervision:** WW.

**Validation:** SL WW.

**Visualization:** SL MG RLG WW.

**Writing – original draft:** SL WW.

**Writing – review & editing:** SL RLG WW.

**References**

1. Chandra A, Copen CE, Stephen EH. Infertility and impaired fecundity in the United States, 1982–2010: data from the National Survey of Family Growth. Natl Health Stat Rep. 2013(67):1–18, 1 p following 9.

2. Macaluso M, Wright-Schnapp TJ, Chandra A, Johnson R, Satterwhite CL, Pulver A, et al. A public health focus on infertility prevention, detection, and management. Fertil Steril. 2010; 93(1):16 e1–0.

3. Suarez SS, Pacey AA. Sperm transport in the female reproductive tract. Hum Reprod Update. 2006; 12 (1):23–37. [https://doi.org/10.1093/humupd/dmi047](https://doi.org/10.1093/humupd/dmi047) PMID: 16272225

4. Abbitt PL, Watson L, Howards S. Abnormalities of the seminal tract causing infertility: diagnosis with endorectal sonography. AJR Am J Roentgenol. 1991; 157(2):337–9. [https://doi.org/10.2214/ajr.157.2.1853818](https://doi.org/10.2214/ajr.157.2.1853818) PMID: 1853818

5. Carballada R, Esponda P. Role of fluid from seminal vesicles and coagulating glands in sperm transport into the uterus and fertility in rats. J Reprod Fertil. 1992; 95(3):639–48. PMID: 1404080
6. Gonzales GF. Function of seminal vesicles and their role on male fertility. Asian J Androl. 2001; 3(4):251–8. PMID: 11753468

7. Diamandis EP, Youssef GM, Olsson AY. An update on human and mouse glandular kallikreins. Clin Biochem. 2004; 37(4):258–60. https://doi.org/10.1016/j.clinbiochem.2003.12.013 PMID: 15003726

8. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev. 1992; 44(1):1–80. PMID: 1313585

9. Prassas I, Eissa A, Podia G, Diamandis EP. Unleashing the therapeutic potential of human kallikrein-related serine proteases. Nat Rev Drug Discov. 2015; 14(3):183–202. https://doi.org/10.1038/nrd4534 PMID: 25698643

10. Lilja H, Oldbring J, Rannevik G, Laurell CB. Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Invest. 1987; 80(2):281–5. https://doi.org/10.1172/JCI113070 PMID: 3611349

11. Lilja H, Abrahamsson PA, Lundwall A. Semogel, the predominant protein in human semen. Primary structure and identification of closely related proteins in the male accessory sex glands and on the spermatozoa. J Biol Chem. 1989; 264(3):1894–900. PMID: 2912989

12. Shaw JL, Diamandis EP. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem. 2007; 53(8):1423–32. https://doi.org/10.1373/clinchem.2007.088104 PMID: 17573418

13. Shaw JL, Petraci C, Watson C, Bocking A, Diamandis EP. Role of tissue kallikrein-related peptidases in cervical mucus remodeling and host defense. Biol Chem. 2008; 389(12):1513–22. https://doi.org/10.1515/BC.2008.171 PMID: 18844451

14. Clements J, Mukhtar A. Glandular kallikreins and prostate-specific antigen are expressed in the human endometrium. J Clin Endocrinol Metab. 1994; 78(6):1536–9. PMID: 7515392

15. Rajapakse S, Yamano N, Ogiwara K, Hirata K, Takahashi S, Takahashi T. Estrogen-dependent expression of the tissue kallikrein gene (Klk1) in the mouse uterus and its implications for endometrial tissue growth. Mol Reprod Dev. 2007; 74(8):1053–63. https://doi.org/10.1002/mrd.20567 PMID: 17219431

16. Courthorn J, Figueroa C, Valdes G. Estrogen and luminal stimulation of rat uterine kallikrein. Biol Reprod. 1997; 56(6):1432–8. PMID: 9166695

17. Rajapakse S, Yamano N, Ogiwara K, Hirata K, Takahashi S, Takahashi T. Estrogen-dependent expression of the tissue kallikrein gene (Klk1) in the mouse uterus and its implications for endometrial tissue growth. Mol Reprod Dev. 2007; 74(2):1513–22. https://doi.org/10.1515/BC.2007.171 PMID: 18844451

18. Couse JF, Lindzey J, Grandien K, Gustafsson JA, Korach KS. Tissue distribution and quantitative analysis of estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbeta) messenger ribonucleic acid in the wild-type and ERalpha-knockout mouse. Endocrinology. 1997; 138(11):4613–21.

19. Winuthayanon W, Hewitt SC, Orvis GD, Behringer RR, Korach KS. Uterine epithelial estrogen receptor alpha is dispensable for proliferation but essential for complete biological and biochemical responses. Proc Natl Acad Sci U S A. 2010; 107(45):19272–7. https://doi.org/10.1073/pnas.1013226107 PMID: 20974921

20. Winuthayanon W, Bernhardt ML, Padilla-Banks E, Myers PH, Edin ML, Hewitt SC, et al. Oviductal estrogen receptor alpha signaling prevents protease-mediated embryo death. Elife. 2015; 4:e10453. https://doi.org/10.7554/eLife.10453 PMID: 26623518

21. Astwood EB. A six-hour assay for the quantitative determination of estrogen. Endocrinology. 1938; 23(1):25–31.

22. Zhang Y, Chen Q, Zhang H, Wang Q, Li R, Jin Y, et al. Aquaporin-dependent excessive intrauterine fluid accumulation is a major contributor in hyper-estrogen induced aberrant embryo implantation. Cell Res. 2015; 25(1):139–42. https://doi.org/10.1038/cr.2014.139 PMID: 25342561

23. Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem. 1990; 194(3):755–63. PMID: 1702714

24. Winuthayanon W, Hewitt SC, Korach KS. Uterine epithelial cell estrogen receptor alpha-dependent and -independent genomic profiles that underlie estrogen responses in mice. Biol Reprod. 2014; 91(5):110. https://doi.org/10.1095/biolreprod.114.120170 PMID: 25210133

25. Muytjens CM, Vasiliov SK, Oikonomopoulou K, Prassas I, Diamandis EP. Putative functions of tissue kallikrein-related peptidases in vaginal fluid. Nat Rev Urol. 2016; 13(10):596–607. https://doi.org/10.1038/nrurol.2016.161 PMID: 27603220

26. Shaw JL, Smith CR, Diamandis EP. Proteomic analysis of human cervico-vaginal fluid. J Proteome Res. 2007; 6(7):2859–65. https://doi.org/10.1021/pr070165s PMID: 17567164

27. Bourgeois L, Brillard-Bourdet M, Deperthes D, Juliano MA, Juliano L, Tremblay RR, et al. Serpin-derived peptide substrates for investigating the substrate specificity of human tissue kallikreins hK1 and hK2. J Biol Chem. 1997; 272(47):29590–5. PMID: 9368023
28. Felber LM, Kundig C, Borgono CA, Chagas JR, Tasinato A, Jichlinski P, et al. Mutant recombinant serpins as highly specific inhibitors of human kallikrein 14. FEBS J. 2006; 273(11):2505–14. https://doi.org/10.1111/j.1742-4658.2006.05257.x PMID: 16704423

29. Robert M, Gibbs BF, Jacobson E, Gagnon C. Characterization of prostate-specific antigen proteolytic activity on its major physiological substrate, the sperm motility inhibitor precursor/semenogelin I. Biochemistry. 1997; 36(13):911–9. https://doi.org/10.1021/bi626158b PMID: 9092810

30. Daunter B, Hill R, Hennessey J, Mackay EV. Seminal plasma biochemistry. I. Preliminary report: a possible mechanism for the liquefaction of human seminal plasma and its relationship to spermatozoal motility. Andrologia. 1981; 13(1):131–41. PMID: 7247044

31. Du Plessis SS, Gokul S, Agarwal A. Semen hyperviscosity: causes, consequences, and cures. Front Biosci (Elite Ed). 2013; 5:224–31.

32. Laflamme BA, Wolfner MF. Identification and function of proteolysis regulators in seminal fluid. Mol Reprod Dev. 2013; 80(2):80–101. https://doi.org/10.1002/mrd.23109270

33. Nelson PS, Clegg N, Arnold H, Ferguson C, Bonham M, White J, et al. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci U S A. 2002; 99(18):11890–5. https://doi.org/10.1073/pnas.182376299 PMID: 12185249

34. Murray SR, Chao J, Lin FK, Chao L. Kallikrein multigene families and the regulation of their expression. J Cardiovasc Pharmacol. 1990; 15 Suppl 6:S7–16.

35. Miki K, Clapham DE. Rheotaxis guides mammalian sperm. Curr Biol. 2013; 23(6):443–52. https://doi.org/10.1016/j.cub.2013.02.007 PMID: 23453951

36. Konishi I, Fuji S, Nonogaki H, Nanbu Y, Iwai T, Mori T. Immunohistochemical analysis of estrogen receptors, progesterone receptors, Ki-67 antigen, and human papillomavirus DNA in normal and neoplastic epithelium of the uterine cervix. Cancer. 1991; 68(6):1340–50. PMID: 1651807

37. Elson DA, Riley RR, Lacey A, Thordarson G, Talamantes FJ, Arbet JM. Sensitivity of the cervical transformation zone to estrogen-induced squamous carcinogenesis. Cancer Res. 2000; 60(5):1267–75. PMID: 10728686

38. Jeong JW, Kwak I, Lee KY, Kim TH, Large MJ, Stewart CL, et al. Foxa2 is essential for mouse endometrial gland development and fertility. Biol Reprod. 2010; 83(3):396–403. https://doi.org/10.1095/biolreprod.109.083154 PMID: 20484741

39. Matsuda Y, Oshio S, Yazaki T, Umeda T, Akihama S. The effect of some proteinase inhibitors on liquefaction of human semen. Hum Reprod. 1994; 9(4):664–8. PMID: 8046020

40. Ou CM, Tang JB, Huang MS, Sudhakar Gandhi PS, Geetha S, Li SH, et al. The mode of reproductive-derived Spink (serine protease inhibitor Kazal-type) action in the modulation of mammalian sperm activity. Int J Androl. 2012; 35(1):52–62. https://doi.org/10.1111/j.1365-2605.2011.01159.x PMID: 21831237

41. Miyata T, Inagi R, Nangaku M, Imasawa T, Sato M, Izuha Y, et al. Overexpression of the serpin megasin induces progressive mesangial cell proliferation and expansion. J Clin Invest. 2002; 109(5):585–93. https://doi.org/10.1172/JCI114336 PMID: 11877466

42. Menez R, Michel S, Muller BH, Bossus M, Ducancel F, Jolivet-Reynaud C, et al. Crystal structure of a ternary complex between human prostate-specific antigen, its substrate acyl intermediate and an activating antibody. J Mol Biol. 2008; 376(4):1021–33. https://doi.org/10.1016/j.jmb.2007.11.052 PMID: 18187150

43. Daimon E, Wada Y. Role of neutrophils in matrix metalloproteinase activity in the preimplantation mouse uterus. Biol Reprod. 2005; 73(1):163–71. https://doi.org/10.1095/biolreprod.104.038539 PMID: 15772259

44. Lu P, Takai K, Weaver VM, Werb Z. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb Perspect Biol. 2011;3(12).

45. Wira CR, Grant-Tschudy KS, Crane-Godreau MA. Epithelial cells in the female reproductive tract: a central role as sentinels of immune protection. Am J Reprod Immunol. 2005; 53(2):65–76. https://doi.org/10.1111/j.1600-0897.2004.00248.x PMID: 15790340

46. Michael IP, Sotiropoulou G, Pampalakis G, Magklara A, Ghosh M, Wasney G, et al. Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. J Biol Chem. 2005; 280(15):14628–35. https://doi.org/10.1074/jbc.M408132200 PMID: 15713679

47. Lilja H. Structure and function of prostatic- and seminal vesicle-secreted proteins involved in the gelation and liquefaction of human semen. Scand J Clin Lab Invest Suppl. 1988; 191:13–20. PMID: 2470129

48. Michael IP, Pampalakis G, Mikolajczyk SD, Malm J, Sotiropoulou G, Diamandis EP. Human tissue kallikrein 5 is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and
potentially in prostate cancer progression. J Biol Chem. 2006; 281(18):12743–50. https://doi.org/10.1074/jbc.M600326200 PMID: 16517595

49. Deraison C, Bonnart C, Lopez F, Besson C, Robinson R, Jayakumar A, et al. LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction. Mol Biol Cell. 2007; 18(9):3607–19. https://doi.org/10.1091/mbc.E07-02-0124 PMID: 17596512

50. Tartaglia-Polcini A, Bonnart C, Micheloni A, Cianfarani F, Andre A, Zambruno G, et al. SPINK5, the defective gene in netherton syndrome, encodes multiple LEKTI isoforms derived from alternative pre-mRNA processing. J Invest Dermatol. 2006; 126(2):315–24. https://doi.org/10.1038/sj.jid.5700015 PMID: 16374478

51. Meyer-Hoffert U, Wu Z, Kantyka T, Fischer J, Latendorf T, Hansmann B, et al. Isolation of SPINK6 in human skin: selective inhibitor of kallikrein-related peptidases. J Biol Chem. 2010; 285(42):32174–81. https://doi.org/10.1074/jbc.M109.091850 PMID: 20667819

52. Yousef GM, Diamandis EP. The New Human Tissue Kallikrein Gene Family: Structure, Function, and Association to Disease. Endocrine Reviews. 2001; 22(2):184–204. https://doi.org/10.1210/edrv.22.2.0424 PMID: 11294823

53. Gipson IK, Spurr-Michaud S, Moccia R, Zhan Q, Toribara N, Ho SB, et al. MUC4 and MUC5B transcripts are the prevalent mucin messenger ribonucleic acids of the human endocervix. Biol Reprod. 1999; 60(1):58–64. PMID: 9858486

54. Rijnders S, Bolscher JG, McDonnell J, Vermeiden JP. Filling time of a lamellar capillary-filling semen analysis chamber is a rapid, precise, and accurate method to assess viscosity of seminal plasma. J Androl. 2007; 28(4):461–5. https://doi.org/10.2164/jandrol.106.002360 PMID: 17409459

55. Rodieck RW. The density recovery profile: a method for the analysis of points in the plane applicable to retinal studies. Vis Neurosci. 1991; 6(2):95–111. PMID: 2049333

56. Green M, Bass S, Spear B. A device for the simple and rapid transcervical transfer of mouse embryos eliminates the need for surgery and potential post-operative complications. Biotechniques. 2009; 47 (5):919–24. https://doi.org/10.2144/000113257 PMID: 20041845

57. Sun ZG, Shi HJ, Gu Z, Wang J, Shen QX. A single intrauterine injection of the serine protease inhibitor 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride reversibly inhibits embryo implantation in mice. Contracept. 2007; 76(3):250–5. https://doi.org/10.1016/j.contraception.2007.05.084 PMID: 17707725

58. Friel AM, Zhang L, Pru CA, Clark NC, McCallum ML, Blok LJ, et al. Progesterone receptor membrane component 1 deficiency attenuates growth while promoting chemosensitivity of human endometrial xenograft tumors. Cancer Lett. 2015; 356(2 Pt B):434–42.